The increasing focus on personalized medicine and innovative treatment options is expected to further boost the GLP-1 market in Asia-Pacific, making it a key area for investment and development
People with a family history of medullary thyroid or patients with multiple endocrine neoplasia syndrome type 2, and people with known serious hypersensitivity, should avoid usage
Frequently Asked Questions In trials at the top maintenance dose, average total body-weight loss was about 8% for liraglutide (Saxenda), 15% for semaglutide 2.4 mg (Wegovy), 21% for tirzepatide 15 mg (Zepbound), and 24% for retatrutide in phase 2
Problems with large vessels include strokes and heart attacks
The label reports that in a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33 percent, with a 90 percent confidence interval of 1.25 to 1.42
Book your aesthetic evaluation here